Vir Biotechnology, Inc.:推进剂量扩展队列,计划于2027年启动注册性试验

美股速递
Feb 24

Vir Biotechnology, Inc. 宣布,其研发项目在剂量扩展队列方面取得了积极进展。公司已制定明确规划,目标在2027年正式启动关键的注册性临床试验。这一战略步骤标志着其在核心疗法开发道路上迈出了重要一步,为后续的监管审批和潜在商业化奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10